Mark O’Mahony
Corporate Officer/Principal at LEAP THERAPEUTICS, INC.
Net worth: 15 850 $ as of 2024-04-29
Mark O’Mahony active positions
| Companies | Position | Start | End |
|---|---|---|---|
| LEAP THERAPEUTICS, INC. | Corporate Officer/Principal | 2010-12-31 | - |
Career history of Mark O’Mahony
Former positions of Mark O’Mahony
| Companies | Position | Start | End |
|---|---|---|---|
Tolerx, Inc.
 Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | Corporate Officer/Principal | 2010-03-22 | 2011-12-18 |
LeukoSite, Inc.
 LeukoSite, Inc. Pharmaceuticals: MajorHealth Technology LeukoSite, Inc. develops drugs for treatment of cancer and inflammatory diseases. It produces drugs to block autoimmune and viral diseases associated with malfunctioning leukocytes or white blood cells. The company was founded in 1992 and is located in Cambridge, MA. | Corporate Officer/Principal | 1999-12-31 | 1999-12-31 |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 1999-12-31 | 1999-12-31 |
DecImmune Therapeutics, Inc.
 DecImmune Therapeutics, Inc. BiotechnologyHealth Technology DecImmune Therapeutics, Inc. develops novel peptides and antibodies for acute and tissue damaging inflammation. It engages in developing an antibody-based therapeutic that can prevent tissue damage and preserve organ function by inhibiting activation of the N2 neoepitope in the innate autoimmune pathway. The company was founded by Michael Carroll, Richard S. Foemmel, and Francis Moore Jr. on March 27, 2001 and is headquartered in Cambridge, MA.^ | Corporate Officer/Principal | - | - |
| Serono Corp. | Corporate Officer/Principal | - | - |
Training of Mark O’Mahony
| University College Dublin | Undergraduate Degree |
| Boston University | Masters Business Admin |
Statistics
International
| United States | 7 |
| Ireland | 2 |
| Israel | 2 |
Operational
| Corporate Officer/Principal | 6 |
| Undergraduate Degree | 1 |
| Masters Business Admin | 1 |
Sectoral
| Health Technology | 6 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| LEAP THERAPEUTICS, INC. | Health Technology |
| Private companies | 5 |
|---|---|
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | Health Technology |
LeukoSite, Inc.
LeukoSite, Inc. Pharmaceuticals: MajorHealth Technology LeukoSite, Inc. develops drugs for treatment of cancer and inflammatory diseases. It produces drugs to block autoimmune and viral diseases associated with malfunctioning leukocytes or white blood cells. The company was founded in 1992 and is located in Cambridge, MA. | Health Technology |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
| Serono Corp. | |
DecImmune Therapeutics, Inc.
DecImmune Therapeutics, Inc. BiotechnologyHealth Technology DecImmune Therapeutics, Inc. develops novel peptides and antibodies for acute and tissue damaging inflammation. It engages in developing an antibody-based therapeutic that can prevent tissue damage and preserve organ function by inhibiting activation of the N2 neoepitope in the innate autoimmune pathway. The company was founded by Michael Carroll, Richard S. Foemmel, and Francis Moore Jr. on March 27, 2001 and is headquartered in Cambridge, MA.^ | Health Technology |
- Stock Market
- Insiders
- Mark O’Mahony
- Experience
